Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Cascadian Therapeutics Inc. (CASC): Seth Klarman Took A Victory Lap

Value investor Seth Klarman disclosed in a recent 13G filing that it tendered all of its 8.7 million stake in Cascadian Therapeutics Inc. (CASC). Cascadian shareholders received a tender offer from Seattle Genetics for $10 a share at the end of January. CASC shares were trading at $3.82 at the end of December. This is another successful biotech investment for Seth Klarman’s Baupost.

Insider Monkey analyzed historical stock picks of Seth Klarman covering the 2002-2016 period. Our analysis showed that Klarman’s biotech stock picks were better than a lot of famous biotech hedge fund managers. You can sign up for our monthly newsletter to find out the details of our Klarman analysis. Alternatively you can get free email alerts whenever we publish an article about Baupost by submitting your email address below:

Seth Klarman
Seth Klarman
Baupost Group

BAUPOST GROUP Seth Klarman

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
The Baupost Group 0 0 0 0 0 0%
Baupost Group GP 0 0 0 0 0 0%
Seth A. Klarman 0 0 0 0 0 0%
Seth Klarman
Seth Klarman
Baupost Group

Page 1 of 5 – SEC Filing



UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934

(Amendment No.
02)*
Cascadian Therapeutics, Inc. 

(Name
of Issuer)
Common Stock

(Title of Class of Securities)

14740B606

(CUSIP Number)

March 31, 2018

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

x
Rule
13d-1(b)

o
Rule
13d-1(c)

o
Rule
13d-1(d)
*
The remainder of this cover page shall be filled out for a reporting person’s
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The
information required in the remainder of this cover page shall not be deemed to
be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).


Follow Cascadian Therapeutics Inc. (NASDAQ:CASC)
Trade (NASDAQ:CASC) Now!
Loading...